Rebif
Links shared publicly online about this topic
Rebif approved for early use in MS | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on January 27, 2012 at 10:01 am By:
Pharmafocus Health News and Pharma
Rebif approved for early use in MS - http://t.co/bsAyTudy
Sanofi’s Lemtrada beats Rebif in new study | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on November 14, 2011 at 3:32 pm By:
Pharmafocus Health News and Pharma
Sanofi’s Lemtrada beats Rebif in new study - http://t.co/gYgviH9Y
Doctors Alleged to Have Been Paid to Prescribe Multiple Sclerosis Drug Rebif
disabled-world.com — “Allegations a company caused false or fraudulent claims to be submitted to the Medicaid program” View full resource at disabled-world.com
Most Recently Shared on May 13, 2011 at 10:25 pm By:
Disabled World Health Advocate and Health News
Doctors Alleged to Have Been Paid to Prescribe Multiple Sclerosis Drug Rebif http://ff.im/-DiXm7
Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting
news-medical.net — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.” View full resource at news-medical.net
Most Recently Shared on April 1, 2010 at 12:09 pm By:
Pregnancy News: Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting: EMD Serono... http://bit.ly/d8ysYj
Merck Serono Submits Application For Extension Of Indication For Rebif(R) In Europe
medicalnewstoday.com — “Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an application to the European Medicines Agency (EMA) to extend the indication of Rebif®, its” View full resource at medicalnewstoday.com
Most Recently Shared on June 29, 2011 at 9:05 am By:
Merck Serono Submits Application For Extension Of Indication For Rebif(R) In Europe http://mnt.to/3XMv #multiplesclerosis
Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed” View full resource at medicalnewstoday.com
Most Recently Shared on March 26, 2010 at 4:10 pm By:
MNT Clinical Trials Health News
Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif http://mnt.to/3ztw #clinicaltrials
Is rebif a good medication for MS? Can anyone tell me about it? - Multiple Sclerosis
healthcentral.com — “I just found out I have MS and I am thinking about taking this medication. ...” View full resource at healthcentral.com
Most Recently Shared on July 15, 2011 at 4:26 pm By:
HealthCentral Tips Health Site
@Kitty_Catrelli Another person had the same question and here is the opinion of a woman taking rebif http://bit.ly/n6Oqp1
Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk
medicalnewstoday.com — “Although Lemtrada (alemtuzumab) was found to be more effective in preventing MS relapses than the older drug - Rebif - it did not prevent multiple sclerosis (MS) from becoming disabling in a late-” View full resource at medicalnewstoday.com
Most Recently Shared on July 11, 2011 at 7:05 pm By:
Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk http://mnt.to/3Y8Z #multiplesclerosis
MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS : National MS Society
nationalmssociety.org — “MS stops people from moving. The National MS Society exists to make sure it doesn't.” View full resource at nationalmssociety.org
Most Recently Shared on January 17, 2012 at 4:43 pm By:
News! MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS http://t.co/xesPKxyl
Genzyme MS drug shines in head-to-head trial with Rebif | InPharm
inpharm.com — “Genzyme--™s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial” View full resource at inpharm.com
Most Recently Shared on April 18, 2011 at 9:53 am By:
Pharmafocus Health News and Pharma
Genzyme MS drug shines in head-to-head trial with Rebif http://goo.gl/fb/6yK45
Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal : National MS Society
nationalmssociety.org — “MS stops people from moving. The National MS Society exists to make sure it doesn't.” View full resource at nationalmssociety.org
Most Recently Shared on December 20, 2011 at 10:24 pm By:
News! Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal http://t.co/PZIyCR1e
PharmaLive: Prime Therapeutics Announces CareCentered Contract with EMD Serono, Inc. for MS Drug Rebif
pharmalive.com — “PharmaLive: Prime Therapeutics Announces CareCentered Contract with EMD Serono, Inc. for MS Drug Rebif” View full resource at pharmalive.com
Most Recently Shared on March 12, 2012 at 3:52 pm By:
Kathleen Starr, Ph.D PhD, Doctor, and Psychologist
Outcomes based contracting: Prime Ther. Announces CareCentered Contract with EMD Serono for MS Drug http://t.co/BOS6CDL6 @myen #pharma #in
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinical Signs Of The Disease
medicalnewstoday.com — “Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) signi” View full resource at medicalnewstoday.com
Most Recently Shared on October 26, 2010 at 3:05 pm By:
Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinica... http://mnt.to/3LJJ
PharmaLive: Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients With Early Signs of Multiple Sclerosis
pharmalive.com — “PharmaLive: Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients With Early Signs of Multiple Sclerosis” View full resource at pharmalive.com
Most Recently Shared on November 18, 2011 at 6:00 pm By:
PharmaLive Pharma and Health News
#Merck #Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients w/Early Signs of #MS: http://t.co/pCuGHH16
REFLEX Study Results Show Treatment with Rebif Delays Conversion to MS in Patients with First Clinical Signs of the Disease - Drugs.com MedNews
drugs.com — “Study met its primary endpoint Risk of converting to multiple sclerosis (McDonald criteria) was reduced by half in patients treated with Rebif 44 mcg three time” View full resource at drugs.com
Most Recently Shared on October 25, 2010 at 2:12 pm By:
Drugs and Devices OW OW Health
REFLEX Study Results Show Treatment with Rebif Delays Conversion to MS in Patients with First Clinical Signs ... http://bit.ly/bzTgZJ #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
Pharmafocus
Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer
-
Disabled World
Disabled World is managed by Lynn and Ian Langtree, a couple dedicated to assisting seniors and people with disabilities.
Advertisement
